

Review of: "[Case Report] Profound Symptom Alleviation in Long-Covid Patients After PAMP-Immunotherapy: Three Case Reports"

Hervé Perron

Potential competing interests: I am presently CSO of GeNeuro

These observations are interesting. Since these are case reports and only three in number, I cannot make any comment on the results, better detailed for the patient who relapsed than for the two others (very briefly presented). Clinical scales, detailed follow-up, and relevant blood parameters are lacking.

This might be an interesting avenue but, as LC patients have heterogeneous underlying “causes,” this may not have the same effects in all of them. It would nonetheless be useful to expand this study and make it compliant with clinical trials regulations. Thus, if confirmed to be beneficial, at least to a subgroup of patients, it could be prescribed to LC patients who are often despaired not to be offered any validated treatment.

A discussion about why and how it could have beneficial effects would then become a need, but clinical efficacy, provided that safety is validated, should be the first objective.